RUNX3 and neoplasm: Survival analysis showed significantly higher survival rates of astrocytoma patients having tumours with high RUNX3 protein level when analysing whole sample set (Log-rank test, χ2=6.11, df=1, p=0.013, Figure 2(d)) and even stronger connection when analysing malignant astrocytomas (grades III-IV) only (Log-rank test, χ2=13.74, df=1, p<0.001, Figure 2(e)).